Searchable abstracts of presentations at key conferences in endocrinology

ea0035s17.3 | Cushings syndrome | ECE2014

Medical therapy for endogenous hypercortisolism

Findling James

The initial therapy for endogenous hypercortisolism (EH) or Cushing’s syndrome (CS) is almost always surgery. However, persistence or recurrence of EH is common and medical therapy may be needed to control the clinical and metabolic derangements associated with EH. Pituitary directed therapies include: Cabergoline, simple and well tolerated, cortisol (F) is normalized in 25-40% of patients but the effect is usually not enduring and Pasireotide, a somatostatin analog, redu...

ea0022p640 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Long-term treatment of Cushing's disease with pasireotide (SOM230): results from a Phase II extension study

Boscaro Marco , Zhang Yilong , Sen Kapildeb , Maldonado Mario , Schoenherr Ulrike , Findling James

Introduction: Pasireotide reduced UFC levels in 22 of 29 patients with Cushing’s disease after 15 days’ treatment (Boscaro et al. JCEM 2009). Of these 22 patients, 5 achieved normalized UFC (UFC-responders) and 17 had reduced but not normalized UFC (UFC-reducers). Results of an extension phase to this study are presented.Methods: Patients with de novo or persistent/recurrent Cushing’s disease received pasireotide 600 μg ...

ea0032p853 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Evaluation of late-night salivary cortisol during a Phase III study with pasireotide in patients with Cushing's disease

Newell-Price John , Petersenn Stephan , Pivonello Rosario , Findling James , Fleseriu Maria , Trovato Andrew , Hughes Gareth , Ligueros-Saylan Monica , Biller Beverly

Introduction: Generously supported by IPSEN)-->Measurement of salivary cortisol is a simple, convenient, accurate and reproducible technique with potential value during the diagnosis/management of hypercortisolism. Current analysis evaluates changes in late-night salivary cortisol (LNSC) during pasireotide treatment in patients with Cushing’s disease (CD).Methods: A 12 m, Phase III study enrolled 162 adult...

ea0063oc3.1 | Cushing's and acromegaly | ECE2019

Osilodrostat provides clinical benefit over 48 weeks in patients with Cushing disease: Results from the LINC 3 study

Pivonello Rosario , Fleseriu Maria , Newell-Price John , Bertagna Xavier , Findling James , Shimatsu Akira , Gu Feng , Auchus Richard , Leelawattana Rattana , Jig Lee Eun , Hee Kim Jung , Lacroix Andre , Laplanche Audrey , O'Connell Paul , M Pedroncelli Alberto , Tauchmanova Libuse , MK Biller Beverly

Introduction: Osilodrosat is a potent oral 11β-hydroxylase inhibitor. During the 24-week, single-arm, open-label period of the Phase III LINC 3 study (NCT02180217), osilodrostat treatment demonstrated rapid, sustained reduction in mean urinary free cortisol (mUFC) in most Cushing disease (CD) patients. In the subsequent 8-week, double-blind, randomized-withdrawal phase, a significantly higher proportion of patients receiving osilodrostat maintained normal mUFC at week (W)...

ea0070oc4.5 | Pituitary and Neuroendocrinology | ECE2020

Durability of response and gender-based analysis from the LINC3 trial of osilodrostat in the treatment in cushing’s disease

Pivonello Rosario , Fleseriu Maria , Newell-Price John , Xavier Bertagna , James Findling , Akira Shimatsu , Feng Gu , Richard Auchus , Rattana Leelawattana , Jig Lee Eun , Hee Kim Jung , Andre Lacroix , Biller Beverly

Introduction: In a Phase II study, osilodrostat, a potent oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD. We report the efficacy and safety of osilodrostat in a large CD patient population (NCT02180217).Methods: In this study, open-label osilodrostat was initiated at 2 mg bid in 137 adults with CD and mUFC > 1.5 × ULN, with dose adjustments every 2 weeks (range 1–30 mg bid) up to ...